SCHEMBL14482195

SCHEMBL14482195

CN1CCN(c2cccc(Nc3ncc(F)c(Nc4ccc5c(n4)N(CC4CC4)CCO5)n3)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSC P53634 1/20 0.50
▸ CCNT1 O60563 3/20 0.49
▸ CDK2 P24941 3/20 0.49
▸ CDK9 P50750 3/20 0.49
▸ CCNE1 P24864 1/20 0.49
▸ NTRK1 P04629 1/20 0.46
▸ NTRK3 Q16288 1/20 0.46
▸ NTRK2 Q16620 1/20 0.46
▸ JAK2 O60674 2/20 0.46
▸ JAK1 P23458 2/20 0.46
▸ BRD4 O60885 3/20 0.45
▸ JAK3 P52333 1/20 0.45
▸ CDK1 P06493 2/20 0.45
▸ CCNB1 P14635 2/20 0.45
▸ CCNA2 P20248 2/20 0.45
▸ CDK7 P50613 2/20 0.45
▸ CCNH P51946 2/20 0.45
▸ EGFR P00533 3/20 0.44
▸ ITK Q08881 1/20 0.44
▸ CCND1 P24385 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14482027 0.97 CTSC (0.49) CTSCCCNT1CDK2CDK9CCNE1
SCHEMBL14481671 0.96 CTSC (0.48) CTSCCCNT1CDK2CDK9CCNE1
SCHEMBL14482034 0.92 JAK2 (0.55) CTSCJAK2JAK1BRD4JAK3
SCHEMBL14481799 0.89 JAK2 (0.54) CTSCJAK2JAK1BRD4JAK3
SCHEMBL12854485 0.86 CTSC (0.48) CTSCCCNT1CDK2CDK9CCNE1
SCHEMBL14482333 0.86 CTSC (0.51) CTSCCCNT1CDK2CDK9CCNE1
SCHEMBL12854486 0.84 CTSC (0.47) CTSCCCNT1CDK2CDK9CCNE1
SCHEMBL12854488 0.83 CTSC (0.47) CTSCCCNT1CDK2CDK9CCNE1
SCHEMBL14481696 0.81 JAK1 (0.55) CTSCNTRK1NTRK3NTRK2JAK2
SCHEMBL2566155 0.80 CCNT1 (0.54) CTSCCCNT1CDK2CDK9CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518937-B2 Pyrimidinediamine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-08-27 — — US disclosed
US-20130012501-A1 PYRIMIDINEDIAMINE KINASE INHIBITORS RIGEL PHARMACEUTICALS, INC. 2013-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012501-A1 PYRIMIDINEDIAMINE KINASE INHIBITORS PLK1, TK1, DTYMK CTSC 2302/4885CCNT1 474/4885CDK2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback